anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cholesteryl ester transfer protein inhibitors of the Formula (I) wherein: R1 is Y, W-X or W-Y W is a carbonyl, thiodarbonyl, sulfinyl or sulfnyl X is O-Y, -S-Y, -N(H)-Y or -N-(Y)2. Y is Z or an optionally substituted 1 to 10 membered straight or branched carbon chain where one or two carbon atoms, other than the connecting carbon can be replaced with O, N (or N oxide) or S (or S oxide). Z is 3 to 8 membered carbocyclic or heterocyclic ring or a bicyclic ring system. R2 is an optionally substituted 1 to 6 membered straight or branched carbon chain where one or two carbon atoms other than the connecting carbon can be replaced with O, N (or N oxide) or S (or S oxide) or an optionally substituted carbocyclic or heterocyclic ring which ring ma be optionally be attached via an (C1-C4)alkyl group. Provided that R2 is not methyl. R3 is hydrogen or Q. Q is an optionally substituted 1 to 6 membered straight or branched carbon chain where one carbon atom other than the connecting carbon can be replaced by O, N (or N oxide) or S (or S oxide).  In particular Q may be substituted by V. V is a 3 to 8 membered carbocyclic or heterocyclic ring or a bicyclic ring system. R4 is Q1 or V1. Q1 is an optionally substituted 1 to 6 membered straight or branched carbon chain where one carbon atom other than the connecting carbon can be replaced by O, N (or N oxide) or S (or S oxide). V1 is a carbocyclic or heterocyclic ring. Wherein R3 must contain V or R4 must contain V1. R5, R6 , R7 and R8  are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T or a 1 to 12 membered straight or branched carbon chain where one or two carbon atoms, other than the connecting carbon can be replaced with O, N (or N oxide) or S (or S oxide). R5 and R6 , or R6 and R7 and/or R7 and R8  may also be taken together and can form at least one optionally substituted 4 to 8 membered ring that is partially saturated or fully unsaturated optionally having 1 to 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Provided that R1 is not (C1-C6)alkyl. Pharmaceutical compositions containing such inhibitors can be used to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and in diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis, cardiovascular diseases, dyslipidemia and vascular complications of diabetes, obesity or endotoxemia in some mammals, including humans.
BACKGROUND: Iris cyst can lead to iridocyclitis, angle closure, secondary glaucoma, corneal decompensation, band keratopathy, cataract, subluxation of the lens, or visual disturbance leading to amblyopia or strabismus. Incomplete removal of cyst can lead to recurrence. Recurrent surgeries are more complicated and compromise prognosis. So, complete removal of cyst with minimal anatomical disturbances is essential for better outcomes.
PURPOSE: To define a new technique of triple treatment therapy for iris cyst management.
SYNOPSIS: Iris cyst was treated in three steps. In the first step, iris cyst aspiration followed by cyst cavity treatment with mitomycin-C was done. After that, cyst cavity was irrigated with balanced salt solution (BSS). In the second step, the anterior cyst wall was removed with a vitrectomy cutter. In the third step, the posterior cyst wall was cauterized with diathermy.
HIGHLIGHTS: In this technique, we chose a minimally invasive approach utilizing two 1-mm incisions leading to less astigmatism. Iridectomy was not performed, which led to a small iris defect postoperatively, and pupilloplasty was not required. Injection of mitomycin-C led to destruction of the cyst wall, and diathermy further reduced the chance of recurrence by destroying the cyst base. Postoperatively, mild corneal edema was noted, which resolved in 1 week. Topical steroids were given to control postoperative inflammation. No recurrence has been noted till 6 months of follow-up. The more conservative approach seemed to result in better visual outcomes.
DISCUSSION: Wide varieties of approaches are available for iris cysts, like laser cystotomy, aspiration, diathermy, cryotherapy, injection of sclerosing agents, and surgery.[1] Yu et al.[2] treated iris cyst in a 60-year-old female with cyst content aspiration using 30G needle, followed by injection of 0.0002 mg/ml mitomycin-C in the cavity for 5 min. BSS wash was given five times at the end. They noted a decrease of 13.3% in endothelial cell count following the procedure. They speculate that transient application of MMC can cause permanent damage to the epithelial and goblet cells that secrete cyst fluid, hence resulting in regression of the cyst. Similarly, Kawaguchi et al.[3] aspirated cyst fluid with a 30G needle and left 0.3 ml of 10-3 mg/ml mitomycin-C for 5 min in the cavity, followed by BSS wash in a 32-year-old female with recurrent iris cyst. They reported a decrease of 4% in endothelial cell count postprocedure. Shen et al.[4] used micro diathermy to treat residual cyst wall attached to the endothelium and base of cyst in four cases. In our case, we have combined cyst aspiration, mitomycin-C, excision using vitrectomy cutter, and diathermy. No recurrence has been observed at the longest follow-up of 3 years. However, a small sample size and less duration of follow-up are the limitations to call it the best approach.
VIDEO LINK: https://youtu.be/EC6WA2TiaAE.
Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
The invention provides a 488nm excited wash-free SNAP-tag probe and a preparation method thereof, the wash-free SNAP-tag probe is a series of wash-free SNAP-tag probes which are designed and synthesized by introducing a spiral ring rigid structure into a 4, 5-position disubstituted naphthalimide dye and can be used for 488nm excitation, and the structural formula is shown as (1). The introduction of rigid structures not only limits intramolecular torsion,the stability and brightness of the fluorescent molecules are improved, and the planarity of the probe molecules is also improved. This results in the SNAP-tag probe molecule forming a strong pi-pi effect in water, resulting in quenching of fluorescence. After the probe molecule is combined with SNAP-tag, the fluorescence of the probe molecule is released, and the maximum fluorescence can be enhanced by 28 times. The series of probes can realize the specific marking of SNAP-tag in living cells, and achieve the purpose of washing-free fluorescence imaging. In addition, due to the improvement of stability and brightness, the series of probes can also be used in the super-resolution fluorescence imaging fields of SIM (structured light microscope), STED (stimulated radiation loss) and the like.
INTRODUCTION: Zhilong Huoxue Tongyu Capsule (ZL) is a Chinese medicine used for the treatment of cardio-cerebral diseases. However, the pharmacological mechanisms underlying its regulation of myocardial ischemia/reperfusion injury (MI/RI) remain unclear.
PURPOSE: This study aims to investigate the effects and mechanisms of ZL on MI/RI in mice.
MATERIALS AND METHODS: C57BL/6J mice were randomly assigned to four groups: Sham group, I/R group, ZL group, and ZLY group. The MI/RI mouse model was established by ligation of the left anterior descending coronary artery for 30 minutes, followed by reperfusion for 120 minutes to restore blood perfusion. Cardiac function was evaluated using cardiac ultrasound. Histopathological changes and myocardial infarction area were assessed using Hematoxylin and eosin (H&E) staining and triphenyltetrazolium chloride (TTC) staining. The changes in oxidative stress- and ferroptosis-related markers were detected. RT-qPCR, Western blot, and ELISA were conducted to further explore the mechanism of ZL in improving MI/RI.
RESULTS: Our findings demonstrated that ZL exerted a protective effect against MI/RI by inhibiting ferroptosis, evidenced by the upregulation of antioxidant enzymes such as GSH and GPX4, coupled with the downregulation of ACSL4, a pro-ferroptosis factor. Furthermore, ZL positively impacted the PI3K/AKT/Nrf2 pathway by promoting ATPase activities and enhancing the relative protein expression of its components. Notably, the administration of a PI3K/AKT inhibitor reversed the antioxidant and anti-ferroptosis effects of ZL to some extent, suggesting a potential role for this pathway in mediating ZL's protective effects.
CONCLUSIONS: ZL protects against MI/RI-induced ferroptosis by modulating the PI3K/AKT signaling pathway, leading to increased Nrf2 expression and activation of the HO-1/GPX4 pathway. These findings shed light on the potential therapeutic mechanisms of ZL in the context of cardiovascular diseases.
The invention relates to healthcare tea and a preparing method thereof, and particularly relates to a wild jujube tea supplementing the center, boosting qi, nourishing blood and calming nerves and a preparing method thereof. The wild jujube tea is prepared from seed of wild jujube, ginseng, wolfiporia extensa, dried orange peel, angelica sinensis, codonopsis pilosula, caulis polygoni multiflori, caulis spatholobi, radix rehmanniae preparata, chrysanthemum and longan and by steps of drying, packaging, sterilizing, bagging, and other preparing processes. Drug actions of a prescription are coordinated. Sour and sweet are combined with the seed of wild jujube to nourish the liver and the yin. A guiding drug is adopted. The combination of the medicines is capable of nourishing blood, calming nerves, clearing heat and relieving fidgetness, thus nourishing yin and blood, nourishing the heart and mind, clearing asthenic fever, and removing symptoms such as insomnia with weakness and irritability and palpitation. Compared with the prior art, the preparing method is simple, maintains beneficial components in each formula, and allows components to supplement each other, and the wild jujube tea has advantages of good taste, low cost, good healthcare effects, and convenience for carrying and drinking.
The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
An automatic identification supply system comprises a setup module, an identification device, an item storage device, and a control device, wherein the control device is connected to the setup module, the identification device and the item storage device. The setup module is configured for a user to set a basic information and an item pickup information. The identification device is configured to identify the user according to the basic information. The item storage device is configured to store at least one item to be received corresponding to the item pickup information. The item storage device includes a pick-up platform for the user to pick up the at least one item to be received. The control device is configured to control the item storage device to provide the at least one item to be received to the user according to the item pickup information when the user identified by the identification device.
PROBLEM TO BE SOLVED: To provide a moisture-absorbent humectant pigment which can give cosmetics providing the skin with fresh and youthful feeling and having excellent moisture-absorbent humectant properties without using collagen and to provide a process for producing the same. SOLUTION: This pigment has its surface coated with soybean protein extracted from soybeans and is produced by dissolving soybean protein in an aq. high-pH alkali soln., dispersing a pigment powder in the resultant soln. under stirring, slowly adding a dil. hydrochloric acid soln. dropwise thereto under stirring until a predetermined low pH is obtd. to precipitate the protein on the surface of the powder, separating the protein-coated powder by filtration, washing it with water, and drying and grinding it.
Per the Schedule of Assessments, upon enrollment, participants will be required to come in for a total of five on site visits. The first visit, also known as the baseline visit, will require participants to provided informed consent after all eligibility criteria is met. Subsequently, participants' Demographics, Medical History, EULAR/ACR classification, and physicians' assessments will be documented. Participants' vital signs will be checked and a thorough physical exam will also be performed after which safety labs will be drawn in addition to a routine urinalysis. Participants will complete outcome surveys and a food frequency questionnaire. Participants' body composition will be measured. Concomitant medications will be reviewed. Each participant will receive nutrition education from an approved MD or a consultation with an approved RD depending on the group to which they have been randomized. Participants who receive consultations with an RD will have seven follow up visits after the baseline visit.
BACKGROUND: Laparoscopic Palomo varicocelectomy using indocyanine green (ICG) fluorescent lymphography (FL) is standardized technique to perform lymphatic sparing and avoid post-operative hydrocele. No data regarding the safety of intratesticular injection of ICG are currently available.
OBJECTIVE: The study aimed to assess the safety and efficacy of this procedure at mid-term follow-up.
STUDY DESIGN: Seventy-two patients (median age 14.5 years) undergoing laparoscopic Palomo varicocelectomy using ICG-FL from January 2019 to July 2022, were enrolled. Operative indication was high-grade varicocele in all patients, associated symptoms in 30/72 (41.7 %) and left testicular hypotrophy in 42/72 (58.3 %). Follow-up included clinical examination at 1, 6, 12 months and scrotal Doppler ultrasonography (US) at 12 months postoperatively to assess varicocele persistence, hydrocele, and injections-related complications.
RESULTS: Lymphatic sparing was achieved using ICG-FL in all cases. No intra-operative complications or adverse reactions secondary to ICG occurred. The median follow-up was 22.8 months (range 11-49). Self-limited scrotal hematoma at the injection site occurred in 1/72 (1.4 %). Intratesticular hypoechoic millimetric area was detected at the injection site in 3/72 (4.2 %) on US. This finding disappeared after 1-year observation in 2/3 cases (66.7 %) (Figure). Persistent grade II varicocele was observed in 4/72 (5.5 %), not requiring re-intervention. No hydrocele occurred and 14/22 (63.6 %) with pre-operative hypotrophy showed catch-up growth.
DISCUSSION: ICG-FL was clinically safe, with no allergy or systemic adverse reactions to the dye reported in this series. No injury directly related to the injection of the dye was clinically observed, except for self-limiting scrotal hematoma in one patient. A millimetric hypoechoic and avascular area in the body of the left testicle at the injection site was found on scrotal US at 1-year follow-up in 3 patients of our series. This finding does not seem to be clinically relevant as patients were asymptomatic and serum tumor markers were normal in all cases. Furthermore, the hypoechoic area with calcifications resolved 1 year later in 2/3 patients. The absence of evolution of this finding seems to exclude the heteroplastic nature. We hypothesized that this finding may be linked to elevated volume and/or pressure of intratesticular injection. Future prospective study with larger series and longer follow-up is needed to assess long-term testicular outcomes.
CONCLUSION: Laparoscopic Palomo varicocelectomy using ICG-FL reported excellent outcomes with low incidence of varicocele persistence and no post-operative hydrocele. These preliminary data also confirmed safety of intratesticular injection of ICG at mid-term follow-up, without specific risks for both testis and patient.
PCT No. PCT/US94/11120 Sec. 371 Date Mar. 15, 1996 Sec. 102(e) Date Mar. 15, 1996 PCT Filed Sep. 29, 1994 PCT Pub. No. WO95/09006 PCT Pub. Date Apr. 6, 1995A composition of matter for application to a body surface or membrane to administer a drug by permeation through the body surface or membrane, the composition comprising, in combination the drug to be administered, in a therapeutically effective amount; and a permeation enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactic ester or a mixture of lactate esters, present in specific concentrations.
All patients will be asked to void before they are transferred to the operating room. Patients will be seen shortly before anesthetic induction (baseline, Visit 1). As this is a pragmatic trial, no restrictions to anesthetic management other than the random allocation to sugammadex or neostigmine are planned.

As part of local standards, it is recommended to maintain a moderate block of 1 to 2 twitch responses to train-of-four (TOF) stimulation throughout surgery.

Randomized treatments will be implemented by clinicians in collaboration with research personnel. Patients will be randomized shortly before the reversal of the neuromuscular block. At the time of randomization, the administration of either neostigmine or sugammadex need to be possible. If e.g. the neuromuscular block is too deep to be reversed with neostigmine, patients will not be randomized and excluded from the study.

The anesthesiologist in charge will be informed on the patient's allocation to either the sugammadex or neostigmine group by an unblinded investigator. Patients will be monitored for twitch responses towards the end of surgery to determine the timing and dose for the reversal agent. The twitch response will be measured using a quantitative, acceleromyographic monitoring device. For sugammadex, 4 mg/kg is recommended if spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts (PTC) and there are no twitch responses to (TOF) stimulation. Alternatively, 2 mg/kg is recommended if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. In the neostigmine group, neostigmine 2.5 mg with glycopyrrolate 0.5 mg will be administered as an initial dose. Neostigmine and glycopyrrolate are to be administered in a fixed ratio, and only if the second twitch in response to TOF stimulation has appeared. The initial dose can be repeated up to a ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate. However, the final decision of the dose will be up to the attending anesthesiologist. The administered dose will be recorded. All patients are required to have a documented TOF ratio \> 0.9 before extubation Visit 2 is one hour after surgery in the post anesthesia care unit (PACU). The third Visit is within 4 to 6 hours after surgery on the regular ward. Visit 4 and 5 will be in the morning and afternoon of the first day after surgery (postoperative day (POD) 1). Visit 5 on the afternoon of POD 1 will be the last follow-up and the end of a patient's participation in the study. Thereafter, data will be recorded from electronical medical records until POD 4 or discharge, whichever comes first.
HYPOTHESIS: Tumor recurrence, bacterial infection, and wound healing remain significant clinical challenges after skin-tumor resection. In this study, we tested the hypothesis that a multifunctional nanocomposite platform containing nanoparticles (NPs) with the photothermal agent IR820 and bioactive drug curcumin (Cur) would be able to prevent tumor recurrence, limit bacterial wound infections, and promote wound healing.
EXPERIMENTS: In this study, we developed a near-infrared light-activated nanocomposite hydrogel system (Hydrogel/Cur@IR820) by incorporating self-assembled NPs (Cur@IR820) in solutions containing Pluronic F127 modified with aldehyde groups (F127-CHO) and polyethyleneimine-grafted F127 (F127-PEI).
FINDINGS: The Hydrogel/Cur@IR820 platform exhibited inherent multifunctional properties, including superior injectability, self-healing behavior, photothermal effects, and free radical scavenging ability. The Cur@IR820 NPs led to photonic hyperthermia and near-infrared (NIR)-triggered Cur release, which drove synergistic therapeutic effects against bacteria and tumor cells. Furthermore, the Hydrogel/Cur@IR820 system promoted wound repair and tissue regeneration by reducing inflammation through the antioxidant properties of Cur. Overall, the results of this study have clinical implications for inhibiting tumor growth, treating bacterial infections, and accelerating tissue regeneration.
More individuals are surviving and living with the effects of stroke, a trend that is expected to continue. Upper extremity limitations present a common, persistent challenge for stroke survivors, impacting quality of life. In addition, links have been found between physical impairment and depression, and depression and stroke-induced cognitive impairment. Music has been shown to exert multimodal effects on individuals and may be used as a mediating stimulus to promote therapeutic change. Furthermore, motor imagery may enhance the effectiveness of upper extremity interventions by engaging the same brain areas that are active in physical movement. The purpose of this study is to investigate the effects of therapeutic instrumental music performance and sensory-enhanced motor imagery on upper limb movement, affect and cognition following a stroke. Participants will be assessed at two baselines, and randomly assigned to one of three intervention groups: therapeutic instrumental music performance, therapeutic instrumental music performance and sensory-enhanced motor imagery, or therapeutic instrumental music performance and motor imagery without sensory enhancement.